Menu Search
Equities

Kiora Pharmaceuticals Inc

KPRX:NAQ

Kiora Pharmaceuticals Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)3.31
  • Today's Change-0.11 / -3.22%
  • Shares traded3.20k
  • 1 Year change-34.33%
  • Beta-0.4414
Data delayed at least 15 minutes, as of Nov 21 2024 20:43 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Kiora Pharmaceuticals Inc had revenues remain flat at 0.00, though the company grew net income from a loss of 13.58m to a smaller loss of 12.51m.
Gross margin--
Net profit margin34.64%
Operating margin30.94%
Return on assets20.40%
Return on equity29.11%
Return on investment22.75%
More ▼

Cash flow in USDView more

In 2023, cash reserves at Kiora Pharmaceuticals Inc fell by 3.55m. Cash Flow from Financing totalled 5.97m or -- of revenues. In addition the company used 9.56m for operations while cash from investing was breakeven.
Cash flow per share1.70
Price/Cash flow per share1.78
Book value per share10.01
Tangible book value per share7.78
More ▼

Balance sheet in USDView more

Kiora Pharmaceuticals Inc uses little or no debt in its capital structure.
Current ratio8.97
Quick ratio--
Total debt/total equity0.00
Total debt/total capital0.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.